Hanmi Pharm. Co., Ltd.

KSE 128940.KS

Hanmi Pharm. Co., Ltd. Revenue Per Share for the year ending December 31, 2023: USD 90.22

Hanmi Pharm. Co., Ltd. Revenue Per Share is USD 90.22 for the year ending December 31, 2023, a 8.95% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Hanmi Pharm. Co., Ltd. Revenue Per Share for the year ending December 31, 2022 was USD 82.81, a 4.58% change year over year.
Hanmi Pharm. Co., Ltd. Revenue Per Share for the year ending December 31, 2021 was USD 79.18, a 2.08% change year over year.
Hanmi Pharm. Co., Ltd. Revenue Per Share for the year ending December 31, 2020 was USD 77.56, a 5.03% change year over year.
Hanmi Pharm. Co., Ltd. Revenue Per Share for the year ending December 31, 2019 was USD 73.85, a 1.51% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

KSE: 128940.KS

Hanmi Pharm. Co., Ltd.

CEO	Mr. Jae-Hyun Park
IPO Date	July 30, 2010
Location	South Korea
Headquarters	14, Wiryeseong-daero
Employees	2,270
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.

Key trends

Past 5 years